Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus

F1000Research

Volumn 4, Issue , 2015, Pages

  Thurman, Joshua ^a   Serkova, Natalie ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3;

CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; GLOMERULUS FILTRATION; HUMAN; KIDNEY FIBROSIS; KIDNEY PERFUSION; LUPUS ERYTHEMATOSUS NEPHRITIS; MOLECULAR IMAGING; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84941002819     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.6587.1     Document Type: Review

References (84)

1. Tsokos GC: Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-21. 22129255 10.1056/NEJMra1100359
2. Pons-Estel GJ Alarcon GS Scofield L: Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257-68. 19136143 10.1016/j.semarthrit.2008.10.007 2813992
3. Urowitz MB Gladman DD Abu-Shakra M: Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol. 1997;24(6):1061-5. 9195509
4. Noone TC Semelka RC Chaney DM: Abdominal imaging studies: comparison of diagnostic accuracies resulting from ultrasound, computed tomography, and magnetic resonance imaging in the same individual. Magn Reson Imaging. 2004;22(1):19-24. 14972390 10.1016/j.mri.2003.01.001
5. Sise C Kusaka M Wetzel LH: Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int. 2000;58(6):2492-501. 11115083 10.1046/j.1523-1755.2000.00433.x
6. Lins CF Santiago MB: Ultrasound evaluation of joints in systemic lupus erythematosus: a systematic review. Eur Radiol. 2015. 25716942 10.1007/s00330-015-3670-y
7. Kao CH Ho YJ Lan JL: Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum. 1999;42(1):61-8. 9920015 10.1002/1529-0131(199901)42:1<61::AID-ANR8>3.0.CO;2-9
8. Serkova NJ Renner B Larsen BA: Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology. 2010;255(2):517-26. 20332377 10.1148/radiol.09091134 2858816
9. Zhang JL Rusinek H Chandarana H: Functional MRI of the kidneys. J Magn Reson Imaging. 2013;37(2):282-93. 23355431 10.1002/jmri.23717 3558841
10. Li X Xu X Zhang Q: Diffusion weighted imaging and blood oxygen level-dependent MR imaging of kidneys in patients with lupus nephritis. J Transl Med. 2014;12:295. 25342208 10.1186/s12967-014-0295-x 4221678
11. Sarbu N Alobeidi F Toledano P: Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev. 2015;14(2):153-9. 25461835 10.1016/j.autrev.2014.11.001
12. Korbet SM Lewis EJ Schwartz MM: Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;35(5):904-14. 10793026
13. Cervera R Khamashta MA Font J: Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999;78(3):167-75. 10352648
14. Jacobsen S Petersen J Ullman S: Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol. 1999;28(2):75-80. 10229135
15. Hanly JG: Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10(6):338-47. 24514913 10.1038/nrrheum.2014.15
16. Bomback AS Appel GB: Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12);2028-35. 21051743 10.1681/ASN.2010050472
17. Cameron JS: Lupus nephritis. J Am Soc Nephrol. 1999;10(2):413-24. 10215343
18. Walsh SJ Algert C Gregorio DI: Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol. 1995;22(9):1663-8. 8523342
19. Bernatsky S Boivin JF Joseph L: Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-7. 16868977 10.1002/art.21955
20. Contreras G Pardo V Cely C: Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005;14(11):890-5. 16335581 10.1191/0961203305lu2238oa
21. Weening JJ D'Agati VD Schwartz MM: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241-50. 14747370 10.1097/01.ASN.0000108969.21691.5D
22. Najafi CC Korbet SM Lewis EJ: Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59(6):2156-63. 11380817 10.1046/j.1523-1755.2001.00730.x
23. Giannico G Fogo AB: Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8(1):138-45. 22977215 10.2215/CJN.03400412
24. Appel GB Contreras G Dooley MA: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-12. 19369404 10.1681/ASN.2008101028 2678035
25. Ginzler EM Dooley MA Aranow C: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219-28. 16306519 10.1056/NEJMoa043731
26. Chan TM Li FK Tang CS: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156-62. 11036121 10.1056/NEJM200010193431604
27. Houssiau FA Vasconcelos C D'Cruz D: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-31. 12209517 10.1002/art.10461
28. Futrell N Schultz LR Millikan C: Central nervous system disease in patients with systemic lupus erythematosus. Neurology. 1992;42(9):1649-57. 1513450
29. Boumpas DT Austin HA 3rd Fessler BJ: Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med. 1995;122(12):940-50. 7755231 10.7326/0003-4819-122-12-199506150-00009
30. Denburg SD Denburg JA: Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus. 2003;12(12):883-90. 14714906 10.1191/0961203303lu497oa
31. Keenan PA Conway J: Psychiatric and neurocognitive concomitants of systemic lupus erythematosus. Ann N Y Acad Sci. 1997;823:69-80. 9292034 10.1111/j.1749-6632.1997.tb48380.x
32. Hanly JG Walsh NM Sangalang V: Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19(5):732-41. 1613703
33. Diamond B Volpe B: On the track of neuropsychiatric lupus. Arthritis Rheum. 2003;48(10):2710-2. 14558073 10.1002/art.11278
34. Leritz E Brandt J Minor M: Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. J Clin Exp Neuropsychol. 2002;24(4):527-33. 12187465 10.1076/jcen.24.4.527.1038
35. Alexander JJ Jacob A Vezina P: Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur J Immunol. 2007;37(6):1691-701. 17523212 10.1002/eji.200636638
36. Zvaifler NJ Bluestein HG: The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum. 1982;25(7):862-6. 7104058 10.1002/art.1780250730
37. Schroeder JO Euler HH: Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Biol. 1989;260:203-13. 2624244 10.1007/978-1-4684-5718-6_21
38. Barile L Lavalle C: Transverse myelitis in systemic lupus erythematosus--the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol. 1992;19(3):370-2. 1578449
39. Boumpas DT Yamada H Patronas NJ: Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med. 1991;81(296):975-84. 1808642 10.1093/qjmed/81.3.975
40. Ramos PC Mendez MJ Ames PR: Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol. 1996;14(3):295-9. 8809444
41. Denburg SD Carbotte RM Denburg JA: Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 1994;37(9):1311-20. 7945494 10.1002/art.1780370907
42. Barile-Fabris L Ariza-Andraca R Olguin-Ortega L: Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620-5. 15769918 10.1136/ard.2004.025528 1755456
43. Austin HA Klippel JH Balow JE: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614-9. 3511372 10.1056/NEJM198603063141004
44. Narváez J Ríos-Rodriguez V de la Fuente D: Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41(3):364-72. 21875742 10.1016/j.semarthrit.2011.06.004
45. Ye Y Qian J Gu Y: Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol. 2011;30(7):981-6. 21340494 10.1007/s10067-011-1714-5
46. Petri M Kasitanon N Lee SS: Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum. 2008;58(6):1784-8. 18512819 10.1002/art.23456
47. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599-608. 10211873 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F
48. Ho A Magder LS Barr SG: Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2342-9. 11665975 10.1002/1529-0131(200110)44:10<2342::AID-ART397>3.0.CO;2-8
49. Toubi E Shoenfeld Y: Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev. 2007;6(3):119-25. 17289545 10.1016/j.autrev.2006.07.004
50. Cervera R Viñas O Ramos-Casals M: Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis. 2003;62(5):431-4. 12695155 10.1136/ard.62.5.431 1754546
51. Amoura Z Koutouzov S Chabre H: Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000;43(1):76-84. 10643702 10.1002/1529-0131(200001)43:1<76::AID-ANR10>3.0.CO;2-I
52. Bigler C Lopez-Trascasa M Potlukova E: Antinucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis. 2008;51(4):624-9. 18371538 10.1053/j.ajkd.2007.10.041
53. Birmingham DJ Irshaid F Nagaraja HN: The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus. 2010;19(11):1272-80. 20605879 10.1177/0961203310371154 3086056
54. Trendelenburg M Marfurt J Gerber I: Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum. 1999;42(1):187-8. 9920031 10.1002/1529-0131(199901)42:1<187::AID-ANR24>3.0.CO;2-U
55. Bonfa E Golombek SJ Kaufman LD: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987;317(5):265-71. 3496538 10.1056/NEJM198707303170503
56. Sanna G Piga M Terryberry JW: Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus. 2000;9(8):573-83. 11035431 10.1191/096120300678828695
57. Williams RC Jr Sugiura K Tan EM: Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2004;50(4):1239-47. 15077307 10.1002/art.20156
58. Lefranc D Launay D Dubucquoi S: Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. Arthritis Rheum. 2007;56(10):3420-32. 17907141 10.1002/art.22863
59. Jongen PJ Doesburg WH Ibrahim-Stappers JL: Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand. 2000;101(2):116-21. 10685859 10.1034/j.1600-0404.2000.101002116.x
60. Fanouriakis A Boumpas DT Bertsias GK: Pathogenesis and treatment of CNS lupus. Curr Opin Rheumatol. 2013;25(5):577-83. 23836074 10.1097/BOR.0b013e328363eaf1
61. Hricak H Crooks L Sheldon P: Nuclear magnetic resonance imaging of the kidney. Radiology. 1983;146(2):425-32. 6849088 10.1148/radiology.146.2.6849088
62. Leung AW Bydder GM Steiner RE: Magnetic resonance imaging of the kidneys. AJR Am J Roentgenol. 1984;143(6):1215-27. 6388280 10.2214/ajr.143.6.1215
63. Zhang JL Morrell G Rusinek H: New magnetic resonance imaging methods in nephrology. Kidney Int. 2014;85(4):768-78. 24067433 10.1038/ki.2013.361 3965662
64. Sibbitt WL Jr Sibbitt RR Brooks WM: Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999;42(10):2026-38. 10524673 10.1002/1529-0131(199910)42:10<2026::AID-ANR2>3.0.CO;2-J
65. Kording F Weidensteiner C Zwick S: Simultaneous assessment of vessel size index, relative blood volume, and vessel permeability in a mouse brain tumor model using a combined spin echo gradient echo echo-planar imaging sequence and viable tumor analysis. J Magn Reson Imaging. 2014;40(6):1310-8. 24390982 10.1002/jmri.24513
66. Hao G Du Y Zhou XJ: Serial non-invasive assessment of antibody induced nephritis in mice using positron emission tomography. PLoS One. 2013;8(2):e57418. 23460853 10.1371/journal.pone.0057418 3584026
67. Otte A Weiner SM Peter HH: Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study. Eur J Nucl Med. 1997;24(7):787-91. 9211766 10.1007/BF00879668
68. Hildebrandt IJ Gambhir SS: Molecular imaging applications for immunology. Clin Immunol. 2004;111(2):210-24. 15137954 10.1016/j.clim.2003.12.018
69. Sargsyan SA Thurman JM: Molecular imaging of autoimmune diseases and inflammation. Mol Imaging. 2012;11(3):251-64. 22554489
70. Kenyon M Parisella MG Visalli N: Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes Metab Res Rev. 2008;24(2):115-22. 17918277 10.1002/dmrr.767
71. Anzola LK Galli F Dierckx RA: SPECT radiopharmaceuticals for imaging chronic inflammatory diseases in the last decade. Q J Nucl Med Mol Imaging. 2015;59(2):197-213. 25669765
72. Ollert MW Kadlec JV David K: Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol. 1994;153(5):2213-21. 8051421
73. Walport MJ: Complement. First of two parts. N Engl J Med. 2001;344(14):1058-66. 11287977 10.1056/NEJM200104053441406
74. Hill GS Delahousse M Nochy D: Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 2001;59(1):304-16. 11135084 10.1046/j.1523-1755.2001.00492.x
75. Thurman JM: Complement in kidney disease: core curriculum 2015. Am J Kidney Dis. 2015;65(1):156-68. 25441433 10.1053/j.ajkd.2014.06.035 4272665
76. Janssen BJ Christodoulidou A McCarthy A: Structure of C3b reveals conformational changes that underlie complement activity. Nature. 2006;444(7116):213-6. 17051160 10.1038/nature05172
77. van den Elsen JM Isenman DE: A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science. 2011;332(6029):608-11. 21527715 10.1126/science.1201954
78. Song H He C Knaak C: Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003;111(12):1875-85. 12813023 10.1172/JCI17348 161422
79. Atkinson C Song H Lu B: Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005;115(9):2444-53. 16127466 10.1172/JCI25208 1190375
80. Sargsyan SA Serkova NJ Renner B: Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int. 2012;81(2):152-9. 21956190 10.1038/ki.2011.332 3375901
81. Thurman JM Kulik L Orth H: Detection of complement activation using monoclonal antibodies against C3d. J Clin Invest. 2013;123(5):2218-30. 23619360 10.1172/JCI65861 3635726
82. Thorek DL Chen AK Czupryna J: Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34(1):23-38. 16496086 10.1007/s10439-005-9002-7
83. Pickering MC Cook HT Warren J: Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 2002;31(4):424-8. 12091909 10.1038/ng912
84. Rovin BH Furie R Latinis K: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-26. 22231479 10.1002/art.34359